Hepatocellular Carcinoma

1st Line

No Prior Therapy

1st Line

No Trials Currently Available

IRB #2377
A humanitarian device exemption use protocol of TheraSphere for treatment of unresectable Hepatocellular Carcinoma

Prior Therapy

2nd line

IRB #15077
9785-CL-3021: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Enzalutamide in Subjects with Advanced Hepatocellular Carcinoma

IRB #11746
IAT-MC-JVDE: Phase 3 Study of Ramucirumab and Best Supportive Care (BSC) Versus Placebo and BSC as Second-Line Treatment in Patients With Hepatocellular Carcinoma and Elevated Baseline Alpha-Fetoprotein (AFP) Following First-Line Therapy With Sorafenib

IRB #15816
A Phase II Study of Pembrolizumab (MK-3475) as Monotherapy in Subjects with Previously Systemically Treated Advanced Hepatocellular Carcinoma (KEYNOTE-224)

IRB #16133
A Phase III Study of Pembrolizumab (MK-3475) vs. Best Supportive Care as Second-Line Therapy in Subjects with Previously Systemically Treated Advanced Hepatocellular Carcinoma (KEYNOTE-240)

Cholangiocarcinoma

1st Line

IRB # 16033
INCB 54828-202: A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy

1st or 2nd Line

IRB# 15816
A Phase II Study of Pembrolizumab (MK-3475) as Monotherapy in Subjects with Previously Systemically Treated Advanced Hepatocellular Carcinoma (KEYNOTE-224)

IRB# 16133
A Phase III Study of Pembrolizumab (MK-3475) vs. Best Supportive Care as Second-Line Therapy in Subjects with Previously Systemically Treated Advanced Hepatocellular Carcinoma (KEYNOTE-240)

http://www.ohsu.edu/research/rda/so/knight.php

Key

Open for Enrollment
In Development
Enrollment on Hold

6/28/2017

GI Hepatobiliary

OHSU
Knight Cancer Institute